|MHC class I-restricted myelin epitopes are cross-presented by Tip-DCs that promote determinant spreading to CD8⁺ T cells.|
|Jump to Full Text|
|PMID: 23291597 Owner: NLM Status: MEDLINE|
|Myelin presentation to T cells in the central nervous system (CNS) sustains inflammation in multiple sclerosis (MS). CD4(+) and CD8(+) T cells contribute to MS, but only cells that present myelin to CD4(+) T cells have been identified. We show that MHC class I-restricted myelin basic protein (MBP) was presented by oligodendrocytes and cross-presented by Tip-dendritic cells (DCs) during experimental autoimmune encephalomyelitis (EAE), an animal model of MS initiated by CD4(+) T cells. Tip-DCs activated naive and effector CD8(+) T cells ex vivo, and naive MBP-specific CD8(+) T cells were activated in the CNS during CD4(+) T cell-induced EAE. These results demonstrate that CD4(+) T cell-mediated CNS autoimmunity leads to determinant spreading to myelin-specific CD8(+) T cells that can directly recognize oligodendrocytes.|
|Qingyong Ji; Luca Castelli; Joan M Goverman|
Related Documents :
|23326377 - Differences in transcription patterns between induced pluripotent stem cells produced f...
23178757 - Chlamydophila pneumoniae in human immortal jurkat cells and primary lymphocytes uncontr...
11776477 - Muscle satellite cells are multipotential stem cells that exhibit myogenic, osteogenic,...
24348757 - Mechanisms of the immunosuppressive effects of mouse adipose tissue-derived mesenchymal...
25263867 - Novel ph-responsive dextrin nanogels for doxorubicin delivery to cancer cells with redu...
11169437 - Identification of a novel dendritic cell-like subset of cd64(+) / cd16(+) blood monocytes.
|Type: Journal Article; Research Support, N.I.H., Extramural Date: 2013-01-06|
|Title: Nature immunology Volume: 14 ISSN: 1529-2916 ISO Abbreviation: Nat. Immunol. Publication Date: 2013 Mar|
|Created Date: 2013-02-18 Completed Date: 2013-04-16 Revised Date: 2013-09-03|
Medline Journal Info:
|Nlm Unique ID: 100941354 Medline TA: Nat Immunol Country: United States|
|Languages: eng Pagination: 254-61 Citation Subset: IM|
|Department of Immunology, University of Washington, Seattle, Washington, USA.|
|APA/MLA Format Download EndNote Download BibTex|
Antigens, CD11c / metabolism
Autoimmunity / immunology
CD4-Positive T-Lymphocytes / immunology
CD8-Positive T-Lymphocytes / immunology*
Central Nervous System / immunology
Dendritic Cells / immunology*
Encephalomyelitis, Autoimmune, Experimental / immunology*
Epitopes / immunology
Lymphocyte Activation / immunology
Mice, Inbred C3H
Monocytes / cytology, metabolism
Multiple Sclerosis / immunology
Myelin Basic Protein / immunology*
Oligodendroglia / immunology
|AI072737/AI/NIAID NIH HHS; AI073748/AI/NIAID NIH HHS; R01 AI072737/AI/NIAID NIH HHS|
|0/Antigens, CD11c; 0/Epitopes; 0/Myelin Basic Protein|
|Nat Immunol. 2013 Mar;14(3):196-7
Journal ID (nlm-journal-id): 100941354
Journal ID (pubmed-jr-id): 21750
Journal ID (nlm-ta): Nat Immunol
Journal ID (iso-abbrev): Nat. Immunol.
nihms-submitted publication date: Day: 12 Month: 2 Year: 2013
Electronic publication date: Day: 06 Month: 1 Year: 2013
Print publication date: Month: 3 Year: 2013
pmc-release publication date: Day: 01 Month: 9 Year: 2013
Volume: 14 Issue: 3
First Page: 254 Last Page: 261
PubMed Id: 23291597
|MHC Class I-Restricted Myelin Epitopes Are Cross-Presented by Tip-DCs That Promote Determinant Spreading to CD8+ T Cells|
|Joan M. Goverman|
|Department of Immunology, University of Washington, Seattle WA 98195
|Correspondence: Correspondence should be addressed to J.M.G., Joan M. Goverman, Ph.D. Professor, University of Washington School of Medicine, Department of Immunology, Box 357650, HSC H474B, 1959 NE Pacific Street, Seattle, WA 98195, Phone: 206-685-7604, Fax: 206-543-1013, email@example.com
Multiple sclerosis (MS) is a central nervous system (CNS) autoimmune disease characterized by inflammatory, demyelinating lesions and axonal loss. MS is believed to be triggered by exposure to environmental factors that activate peripheral myelin-specific T cells, allowing them to cross the blood brain barrier that normally restricts entry of naïve T cells. The pathogenesis of MS has been studied in experimental autoimmune encephalomyelitis (EAE), an animal model of MS that is induced by immunization with myelin antigens1. Infiltrating CD4+ T cells are re-activated within the CNS by local antigen-presenting cells (APCs) presenting MHC class II-restricted myelin epitopes2,3. CD11c+ dendritic cells (DCs) are critical for this re-activation step4. The ensuing inflammatory response recruits both monocytes that differentiate into MHC class II+ APCs after entering the CNS5,6, and naïve T cells that recognize myelin epitopes distinct from those recognized by the initial T cell population. Activation of these naive T cells leads to a phenomenon known as determinant spreading7,8 that is important for sustaining chronic inflammation.
The mechanisms studied in EAE center on the activity of myelin-specific CD4+ T cells. However, CD8+ T cells are strongly implicated in the pathogenesis of MS9,10. CD8+ T cells outnumber CD4+ T cells in both acute and chronic MS lesions11,12. The number of CD8+ T cells and macrophages also correlates with the extent of axonal damage13,14. CD8+ T cells appear more antigen-experienced than CD4+ T cells in the CNS and blood of MS patients, and CD8+ but not CD4+ T cell clones persist over time in both of these compartments11,15–17. Neuroantigen-specific CD8+, but not CD4+, T cells are also more abundant in the CNS in MS patients compared to healthy controls18,19. The contribution of CD8+ T cells to CNS autoimmunity is not well understood. Some studies attribute an immunoregulatory function to CD8+ T cells in CD4+ T cell-induced EAE10, although the antigen specificity of the CD8+ T cells in these studies was not defined. Other studies have shown that myelin-specific CD8+ T cells can not only potentiate CD4+ T cell-mediated EAE20, but also mediate CNS autoimmune disease on their own21–23. These diverse results suggest that CD8+ T cells may play a complex role in CNS autoimmunity that can result in exacerbation or amelioration of disease.
Myelin-specific CD8+ T cells must recognize their cognate antigen within the CNS to influence inflammatory responses; however, APCs presenting MHC class I-restricted myelin epitopes have not been identified. We generated unique reagents to detect a MHC class I-restricted epitope of myelin basic protein (MBP) on the surface of APCs. We analyzed CNS cells from mice with EAE induced by CD4+ rather than CD8+ T cells to eliminate the possibility that activated CD8+ T cells may lyse APCs presenting their cognate antigen and prevent their detection. We found that MBP was cross-presented by Tip-DCs derived from inflammatory monocytes that accumulated in the CNS during CD4+ T cell-mediated EAE. These DCs were the only CNS cells capable of activating naïve CD8+ T cells directly ex vivo. Consistent with this, we show that naïve CD8+ MBP-specific T cells were recruited to the CNS during EAE and activated in situ, demonstrating that determinant spreading to CD8+ T cells can occur during CD4+ T cell-induced EAE. MHC class I-restricted MBP was also directly presented by oligodendrocytes that were induced to express MHC class I during EAE, indicating that these cells as well as the Tip-DCs are potential targets of myelin-specific CD8+ T cells in the CNS.
To identify CNS cells that present MHC class I-restricted MBP, we utilized 8.6 TCR transgenic T cells generated in C3HeB/Fej mice that are specific for MBP79–87 presented by H-2Kk (referred to as MBP H2-Kk)24. CD8+ TCR transgenic 8.6 T cells become tolerized in wild-type mice; however, they can be isolated from MBP-deficient mice and used to detect cells presenting endogenous MBP epitopes directly ex vivo24. To maximize the sensitivity of detection of MBP H2-Kk epitope in this assay, we generated effector CD8+ 8.6 T cells that secrete interferon-γ (IFN-γ) rapidly upon exposure to APCs presenting MBP–H2-Kk. We first assessed whether bulk CNS cells from mice with CD4+ T cell-mediated EAE or from healthy mice could stimulate CD8+ 8.6 T cell responses directly ex vivo. CNS cells were isolated from C3HeB/Fej mice at the peak of EAE induced by immunization with recombinant myelin oligodendrocyte glycoprotein (rMOG), which activates encephalitogenic CD4+ T cells in this strain25. Exposure of 8.6 T cells to bulk mononuclear CNS cells isolated from mice with EAE triggered IFN- γ production (Fig. 1a). CNS cells from healthy mice triggered a smaller but detectable percentage of 8.6 effector T cells to produce IFN- γ, indicating that MBP–H2-Kk is presented constitutively at low abundance in the CNS.
We also generated an antibody specific for the MBP–H2-Kk complex by immunizing C3HeB/Fej mice with recombinant H2-Kk protein that was refolded with β2 microglobulin and MBP79–87 peptide. A cell-based ELISA assay was employed to identify antibodies that bind specifically to RMA-S–H2-Kk cells pulsed with MBP79–87 peptide26. Over 20 MBP–H2-Kk–specific hybridomas were generated; the antibody designated 12H4 was used in the majority of our studies. Specificity of the 12H4 antibody was confirmed by showing that 12H4 binds to RMA-S–H2-Kk cells pulsed with MBP79–87 but not to RMA-S–H2-Kk cells pulsed with SV40 T antigen (TAg) peptide that also associates with H2-Kk (Fig. 1b). The 12H4 antibody also specifically inhibits IFN- γ production by 8.6 effector T cells in response to either MBP79–87-pulsed splenocytes or CNS cells presenting endogenous MBP, but did not inhibit the response of TAg-specific T cells to splenocytes pulsed with TAg peptide (Fig. 1c).
The 12H4 antibody was used to identify which CNS cell types express MBP–H2-Kk, and these populations were sorted and incubated with 8.6 effector T cells to determine whether these cell types could trigger functional T cell responses. CNS cells from EAE mice were stained with 12H4 and a panel of antibodies specific for cell-surface markers that identify DCs, macrophages and microglia. Gating strategies used for analyses and sorting of the CNS cell types are shown in Supplementary Fig. 1. CD11c+ cells accounted for the highest percentage of 12H4+ cells and stimulated the most IFN- γ production by 8.6 effector T cells (Fig. 2a, b). The percentage of 12H4+ macrophages was less compared to 12H4+ CD11c+ DCs (Fig. 2a and Supplementary Fig. 2a), which may account for the reduced IFN- γ production by 8.6 T cells incubated with macrophages (Fig. 2b). Only a small percentage of microglia were 12H4+ (Fig. 2a), and the IFN- γ production elicited by microglia was only slightly above background (Fig. 2b). Although there were fewer DCs than macrophages in the CNS infiltrate, the absolute number of 12H4+ DCs was greater than the number of 12H4+ macrophage (Supplementary Fig. 2b). Thus, CD11c+ DCs are the predominant APCs presenting MBP–H2-Kk shortly after onset of CD4+ T cell-mediated EAE and microglia contribute only marginally toward presenting MHC class I-restricted MBP at this time point.
The majority of CD11c+ cells in the CNS of rMOG-immunized C3HeB/Fej mice expressed CD11b (Supplementary Fig. 3), consistent with the predominance of myeloid DCs (mDCs) in the CNS reported for other CD4+ T cell-mediated EAE models4,27–29. 12H4+ DCs were also CD11b+; the few CD11c+CD8+ and CD11c+B220+ DCs detected in the CNS did not present MBP–H2-Kk (Supplementary Fig. 3). Previous studies demonstrated that both mDCs and macrophages that accumulate in the CNS during CD4+ T cell-mediated EAE arise primarily from CD11b+Ly6C+CD62L+F4/80+ inflammatory monocytes that infiltrate the CNS via a CCR2-dependent mechanism5,6,30. The 12H4+ DCs also exhibited a CD11c+CD11b+Ly6C+F4/80+MHC class II+CX3CR1− phenotype consistent with cells differentiated from inflammatory monocytes (Fig. 3), although the 12H4+ DCs were CD62L−. CCR2 expression on 12H4+ DCs also differed from monocytes in that it ranged from intermediate to negative. Down-regulation of CCR2 by monocytes entering an environment with elevated expression of interleukin 1 (IL-1) and tumor necrosis factor (TNF) has been previously described31, and this may be the case for CD62L as well.
Because not all of the mDCs in the CNS were 12H4+, we investigated whether this subset exhibited any similarities to other DC subsets known to be proficient in cross-presentation. The spleen contains a DC subset that is proficient in cross-presentation and exhibits a unique CD8αα+CD11b− CD205+ phenotype32 with variable expression of CD103 (ref. 33). This DC subset is generated via a distinct differentiation program dependent on the transcription factors Batf3 and IRF8 as well as the inhibitor of DNA protein Id2 (ref. 34). Non-lymphoid tissues also contain Batf3–IRF8–Id2 lineage DCs that are proficient in cross-presentation and are phenotypically similar (CD11b− CD103+CD205+) to splenic CD8+ DCs except that they do not express CD8 (ref. 34). The MBP–H2-Kk APCs in the CNS of EAE mice differ from these DC subsets in that they were CD11b+ (Fig. 3) and CD205− (data not shown). We analyzed expression of CD103 on 12H4+ cells to determine if expression of this integrin was shared by cells proficient in cross-presentation. A broad range of CD103 expression was observed on CD11c+ cells in the CNS, with cells that expressed an intermediate amount of CD11b expressing the most CD103 (Fig. 4a, top). However, these CD103HiCD11bInt cells did not present MBP–H2-Kk. Instead, MBP–H2-Kk was expressed only on cells expressing intermediate amounts of CD103 (Fig. 4a, bottom), which corresponded to cells expressing the most CD11b. Together, the expression patterns of CD11b and CD103 define a unique CD11bHiCD103Int phenotype for MBP–H2-Kk+ cells that differs from that seen on other DCs specialized in cross-presentation.
To further confirm that MBP–H2-Kk DCs are distinct from peripheral DCs specialized in cross-presentation, we compared the expression of Batf3, IRF8 and Id2 in 12H4+CD103Int and 12H4− CD103− DCs sorted from the CNS of EAE mice to that seen in CD8+ and CD8− DCs sorted from the spleen. We also analyzed expression of TLR3 and the chemokine receptor XCR1 that is expressed on CD8αα+ DCs in the mouse and the human homolog of these DCs in the human, both of which are frequently observed on cross-presenting DCs in the periphery. As expected, splenic CD8+ DCs expressed significantly more IRF8, Id2, TLR3, Batf3 and XCR1 transcripts compared to CD8− DCs, (Fig. 4b). In contrast, no significant differences in expression of any of these transcripts were observed between 12H4− CD103− and 12H4+CD103Int CNS DCs (Fig. 4b). Taken together, the phenotype and gene expression pattern are not consistent with MBP–H2-Kk+ DCs arising from the same Batf3–IRF8–Id2 lineage as peripheral DCs that are specialized in cross-presentation, supporting the notion that MBP–H2-Kk DCs originate from inflammatory monocytes. We then analyzed the expression in MBP–H2-Kk APCs of ZBTB46, a transcription factor whose expression distinguishes classical DCs from other immune cells35, 36. Both CD8+ and CD8− splenic DCs expressed ZBTB46 and low expression was detected in 12H4 CD103− DCs as well. In contrast, ZBTB46 was not detected in 12H4+CD103Int DCs (Fig. 4b), indicating that they are not derived from the classical DC lineage.
We investigated whether MBP–H2-Kk+ DCs were Tip-DCs characterized by TNF and inducible nitric oxide synthase (iNOS) expression37 that are derived from activated monocytes rather than the classical DC lineage35,36. Approximately 50% of MBP–H2-Kk+ DCs isolated from EAE mice expressed TNF directly ex vivo, and iNOS was also preferentially expressed in 12H4+CD103Int DCs compared to 12H4− CD103− DCs (Fig. 5a). Only low amounts of IL-12 were detected in 12H4+ and 12H4− CNS DCs in EAE mice (data not shown). Interestingly, MBP H2-Kk+ DCs lacked CCR7 expression (Fig. 5a), while 12H4− CD103− DCs express high levels of transcripts encoding this chemokine receptor. Together, these data indicate that MBP–H2-Kk+ APCs are Tip-DCs derived from inflammatory monocytes that infiltrate the inflamed CNS and do not traffic to draining lymph nodes.
To confirm that the Tip-DCs are cross-presenting MBP rather than synthesizing MBP and directly presenting it, we analyzed 12H4+CD103Int and 12H4− CD103− cells isolated from EAE mice for expression of classic and golli-MBP transcripts. Golli-MBPs are a family of proteins that are not incorporated into myelin but that are encoded in part by exons shared with classic MBPs, including the exon that encodes MBP79–87. Golli-MBPs are expressed in the nervous system and by multiple types of immune cells, including DCs38. Oligonucleotide primers specific for a classic-MBP-specific transcript amplified a strong signal from CNS tissue but did not amplify transcripts from either 12H4+CD103Int or 12H4− CD103− DCs (data not shown). As expected, golli-MBP transcripts were detected in DCs, however; the signal was actually stronger in the 12H4− CD103− DCs, which do not express MBP H2-Kk on the surface (Fig. 5b). Similarly, we have not detected 12H4+ thymocytes or 12H4+ T cells in peripheral lymphoid tissues, even though these cells synthesize golli-MBP (data not shown). This result indicates that the expression of MBP–H2-Kk on the surface of DC occurs via cross-presentation of exogenous myelin.
Previous studies of determinant spreading showed that naive, myelin-specific CD4+ T recruited to the CNS during EAE are activated in situ rather than in peripheral lymph nodes28. To determine if the MBP–H2-Kk+ DCs could promote determinant spreading to naive CD8+ T cells, we investigated whether they could activate naive CD8+ T cells. CD11c+ DCs, macrophages and microglia were sorted from the CNS of EAE mice and cultured with naïve 8.6 T cells. The 8.6 T cells proliferated only in response to DCs presenting endogenous MBP (Fig. 5c). To determine if naive CD8+ T cells infiltrate the CNS during EAE and become activated by MBP–H2-Kk+APCs, we utilized a different TCR transgenic line in which the T cells are specific for the same MBP–H2-Kk epitope but do not undergo T cell tolerance, allowing the periphery to be populated with non-activated MBP-specific CD8+ T cells (8.8 mice)24. EAE was induced by adoptive transfer of genetically marked CD4+ rMOG-specific T cells into 8.8 mice, and cells isolated from the CNS and spleen at the peak of disease were analyzed by flow cytometry. Host 8.8 T cells represented an average of 11% of the total T cell population in the CNS (data not shown, n = 9), demonstrating that CD8+ 8.8 T cells that had not been activated in the periphery enter the CNS during CD4+ T cell-induced EAE. While the 8.8 T cells in the spleen exhibited a naive phenotype, the 8.8 T cells in the CNS exhibited an activated phenotype (CD44HiCD62LLoCD69Hi) in the CNS (Fig. 5d). It is possible that the 8.8 CD8+ T cells are activated in the cervical lymph nodes rather than within the CNS; however, 12H4+ DCs were barely detectable in cervical lymph nodes and the percentage of 12H4+ DCs in CNS cells was typically much higher than that seen in lymph nodes (Supplementary Fig. 4). Together these results support the notion that MBP–H2-Kk+ DCs generated in the CNS during CD4+ T cell-induced EAE are capable of activating CD8+ T cells specific for a different myelin epitope that infiltrate the inflamed tissue.
Under healthy conditions, non-hematopoietic CNS cells do not express MHC molecules. We investigated whether the inflammatory milieu generated during CD4+ T cell-mediated EAE induced MHC class I expression on these cells, allowing them to present MBP–H2-Kk. Oligodendrocytes are of particular interest as they synthesize MBP. Astrocytes also present antigen to CD8+ and CD4+ T cells under some circumstances39. Cerebral endothelial cells have also been reported to present peptide that was non-invasively injected into the CNS to CD8+ T cells40, suggesting that these cells might present MBP peptides derived from degraded myelin during EAE. The 12H4 antibody was used to detect presentation of MBP–H2-Kk by these cells, and the individual cell types were sorted from the CNS of EAE mice and cultured with effector 8.6 T cells to detect functional antigen presentation. No MBP H2-Kk complexes were detected on astrocytes or endothelial cells and neither cell type stimulated IFN- γ production by effector 8.6 T cells (Supplementary Fig. 5). In contrast, MBP–H2-Kk was detected on oligodendrocytes in EAE mice (Fig. 6a), and these cells triggered IFN- γ production by 8.6 effector T cells (Fig. 6b), indicating that oligodendrocytes could be direct targets of MBP-specific CD8+ T cells under inflammatory conditions.
The observation that some oligodendrocytes express MBP–H2-Kk shortly after the onset of clinical disease suggested the possibility that CD8 T cell-mediated lysis of oligodendrocytes may be required to provide a source of MBP that is then presented by DCs. To investigate this possibility, we analyzed MBP–H2-Kk expression on oligodendrocytes and CD45+ APCs during the preclinical stage of EAE. In mice induced for CD4+ T cell-mediated EAE, MBP–H2-Kk expression was detected on CD45+ CNS cells harvested from the mice prior to onset of clinical signs (Supplementary Fig. 6). In contrast, a low amount of MHC class I was detected on oligodendrocytes but the cells did not yet express MBP–H2-Kk. These data indicate that MBP–H2-Kk expression on oligodendrocytes is not required prior to expression on DCs and macrophages.
The healthy CNS must contain MBP–H2-Kk+ APCs because adoptive transfer of MBP-specific CD8+ T cells triggers autoimmunity in the absence of CD4+ T cells41. Staining with 12H4 detected MBP–H2-Kk on DCs and macrophages in naive mice, while microglia expressed very little MHC class I and no detectable MBP H2-Kk (Fig. 7a). Different cell types were sorted from the CNS of healthy mice and cultured with effector 8.6 T cells; DCs and macrophages were sorted together due to their low numbers in the healthy CNS. Only the pooled DC-macrophage fraction triggered IFN- γ production by effector CD8+ T cells (Fig. 7b), indicating that resident DCs and/or macrophages in the healthy CNS constitutively present MBP–H2-Kk.
Consistent with a lack of inflammation, CNS DCs in healthy mice expressed less CD80 and CD86 compared to CNS DCs from sick mice (Fig. 7c). The MBP–H2-Kk+ CNS DCs in healthy mice were Ly6C− CD11b+F4/80+CD103− and expressed CX3CR1 and CCR2 (Fig. 7d). Thus, MBP H2-Kk+ DCs in the healthy CNS exhibit a non-inflammatory phenotype distinct from both cross-presenting DCs in peripheral tissues and from CNS DCs observed under the inflammatory conditions of EAE.
APCs that present myelin antigen in the CNS activate the T cells that propagate the inflammatory response and therefore could be therapeutic targets in MS. Although there is compelling evidence that both CD8+ and CD4+ T cells contribute to the pathogenesis of MS, only APCs that present myelin antigen to CD4+ T cells have been characterized. In animal models of MS, both pathogenic and immunoregulatory activities have been attributed to CD8+ T cells. While the mechanisms underlying either of these potential activities are not known, they may reflect interactions with different types of APCs.
We used CD8+ TCR transgenic T cells specific for a MHC class I-restricted epitope of MBP and a newly generated antibody specific for the same epitope to identify cells that present MHC class I-restricted MBP to CD8+ T cells. Although it is not known whether CD4+ or CD8+ T cells initiate MS, we chose to use a CD4+ T cell-mediated EAE model for these studies for two reasons. First, mice expressing myelin-specific CD4+ transgenic TCRs develop spontaneous EAE with many similarities to MS, supporting the idea that models in which CD4+ T cells initiate disease are physiologically relevant to MS1. Second, the disease would initially involve predominantly activated CD4+ T cells, minimizing the possibility that activated myelin-specific CD8+ T cells infiltrating the CNS would lyse APCs presenting their cognate antigen and prevent their detection. We show in CD4+ T cell-mediated EAE that MHC class I-restricted MBP is predominantly presented by DCs whose phenotype and function indicate that they are Tip-DCs, and that these DCs can activate naive MBP-specific CD8+ T cells. Macrophages are much less efficient in presenting MBP–H2-Kk, and microglia, astrocytes and endothelial cells do not present MBP to CD8+ T cells. Oligodendrocytes are induced to express MHC class I and present MBP–H2-Kk under the inflammatory conditions generated during CD4+ T cell mediated EAE.
Presentation of MBP–H2-Kk largely by DCs is consistent with the critical role that DCs play in promoting inflammation during CNS autoimmune disease. In MS patients, DCs accumulate in the meninges and parenchymal lesions4,42,43, and mature DCs are observed lining the blood vessels in non-inflamed CNS tissue where they are well-positioned to re-activate infiltrating T cells4. In CD4+ T cell-mediated EAE, DCs are required to initiate disease4, and CD11b+ mDCs were the only cells that could activate naive CD4+ T cells, even though macrophages phagocytosed comparable amounts of myelin and could activate effector CD4+ T cells28. Interestingly, the pro-inflammatory DCs present early in CD4+ T cell-mediated EAE appear to be replaced later in the disease course with more immature DCs that are less efficient in stimulating CD4+ T cells29. The mechanism responsible for the decline in pro-inflammatory DCs has not been described.
Our data demonstrate that the DCs generated in the CNS during CD4+ T cell-induced EAE that present MHC class I-restricted MBP are CD11b+ Tip-DCs that are likely derived from infiltrating inflammatory monocytes. This conclusion is based on the phenotypic similarity to inflammatory monocytes, the predominant production of TNF and iNOS without IL-12, and the lack of expression of the ZBTB46 transcription that is selectively expressed by classical DCs and their progenitors35, 36. The MBP–H2-Kk+ DCs are also distinguished by their intermediate expression of CD103, an integrin whose expression is correlated with, but not required for, cross-presentation by DCs33. Neither CD103− nor CD103Hi DCs present MBP–H2-Kk, and virtually all CD103Int DCs are 12H4+, indicating that the MBP–H2-Kk+ DCs are a distinct DC subset that can be phenotypically defined by these markers. Importantly, our data demonstrate that presentation of MBP–H2-Kk by Tip-DCs occurs via cross-presentation. Expression of classic MBP was not detected in the MBP–H2-Kk+ DCs, and the low amount of golli-MBP expression was not sufficient to allow direct presentation of MBP H2-Kk because 12H4− DCs expressed as much or more golli-MBP transcripts as 12H4+ DCs.
There are several mechanisms by which the Tip-DCs could acquire and present MBP–H2-Kk. Tip-DCs could phagocytose myelin debris or dead oligodendrocytes and transfer the antigen to the cytosol where it is processed and loaded onto MHC class I molecules for cross-presentation. Oligodendrocytes have also been shown to produce exosomes containing myelin epitopes under steady state conditions that are preferentially taken up by microglia44. If these exosomes are taken up under inflammatory conditions by macrophage and DCs, they could be a potential source of MBP peptides for these APCs during EAE, similar to bone marrow-derived DCs that obtain antigen from exosomes and load it onto their own MHC class I molecules45. An alternative possibility is that the Tip-DCs acquire pre-formed MBP peptide–MHC class I complexes from the membranes of neighboring cells such as oligodendrocytes via trogocytosis46,47. This cell-contact dependent process has recently been shown to result in “cross-dressed” DCs that are capable of activating both naïve and memory CD8+ T cells in vitro45. However, cross-dressed DCs are not able to activate naïve CD8+ T cells in vivo, at least in the context of a viral infection. As our data show that naïve CD8+ cells enter the CNS and are activated in situ, cross-dressing seems an unlikely mechanism for presentation of MBP–H2-Kk by Tip-DCs.
Our findings indicate that determinant spreading can occur within the CNS between CD4+ and CD8+ myelin-specific T cells. The Tip-DCs are likely the only cell type in the CNS capable of activating the naive CD8+ T cells as these are the only cells that activated naive 8.8 T cells directly ex vivo. CD8+ T cell activation within the CNS is consistent with the lack of CCR7 on MBP–H2-Kk+ DCs, as this chemokine receptor facilitates trafficking of classical DCs from peripheral tissues to lymph nodes. CCR7 is expressed on MBP–H2-Kk DCs in the inflamed CNS, and DCs that cross-present tumor antigens acquired in the CNS under less inflammatory conditions migrate to peripheral lymph nodes48. Thus, lack of CCR7 may be a characteristic of Tip DCs in inflamed tissues.
DCs are also the predominant APCs that present MBP–H2-Kk in the healthy CNS. The MBP–H2-Kk+ CNS DCs in healthy mice do not exhibit the inflammatory phenotype of the DCs in EAE mice, but their CD11b+CD103− F4/80+ phenotype also does not resemble other tissue resident DCs specialized in cross-presentation. The co-expression of CCR2 and CX3CR1 on these DCs is unusual, although it is not known whether either chemokine receptor is required for their localization in the healthy CNS. APCs that reactivate infiltrating myelin-specific T cells are found in the subarachnoid space37,49; and the role of particular chemokine receptors in facilitating entry of DCs into this compartment is not known. MBP H2-Kk+ APCs in the healthy CNS are capable of stimulating previously activated CD8+ T cells in vitro, suggesting that they have the potential to re-activate CD8+ T cells that had been primed in the periphery.
Our data demonstrate that oligodendrocytes may be lytic targets of activated, MBP-specific CD8+ T cells during EAE, consistent with reports that human MBP-specific CD8+ T cells can lyse oligodendrocytes in a MHC-restricted fashion without addition of exogenous antigen50, and that CD8+ T cells containing polarized cytolytic granules are seen in close proximity to oligodendrocytes and demyelinated axons in the CNS of MS patients14. Because RNA transport mechanisms allow MBP synthesis to take place within myelin membranes distal from the oligodendrocyte cell body, MBP–H2-Kk complexes could be expressed on the myelin sheath where they can engage CD8+ T cells. Endothelial cells and astrocytes did not present MBP–H2-Kk, suggesting that astrocytes contribute to CD8+ T cell activation primarily via cytokine production9, and that endothelial cells do not play a role in enhancing CD8+ T cell recruitment to the CNS via MBP peptide presentation40.
Our findings that MHC class-I-restricted MBP is presented by both Tip-DCs and by oligodendrocytes suggest the intriguing hypothesis that CD8+ T cells could exert both pathogenic and immunoregulatory activities in the CNS during EAE. CD8+ T cells activated by Tip-DCs could exacerbate disease via production of IFN-γ, and the CD8+ T cells could also contribute to tissue damage by lysing oligodendrocytes. However, the Tip-DCs themselves could also become lytic targets of the newly activated CD8+ T cells. Loss of these DCs may reduce inflammation by decreasing the number of APCs available to stimulate both CD4+ and CD8+ T cells in the CNS. Ongoing axonal destruction in inactive MS lesions that appear to have few inflammatory cells (referred to as “low-burning” axonal damage) has been described51 and it is possible that myelin-specific CD8+ T cells may play an important role in this process. It would also be of interest to determine if there is an increase in myelin-specific CD8+ T cell activity during the transition from relapsing/remitting to secondary progressive MS, as this phase of disease is characterized by a decrease in inflammation with ongoing axonal degeneration.
C3HeB/Fej mice from The Jackson Laboratory were bred in house. TCR transgenic 8.6 and 8.8 mice have been described24. Mice expressing transgenic GFP promoted by the PLP promoter (PLP-GFP) were provided by W. Macklin (University of Colorado, Denver, CO), and mice expressing transgenic GFP promoted by the astrocyte-specific human glial fibrillary acidic protein promoter (GFAP-GFP) were from The Jackson Laboratory. PLP-GFP and GFAP-GFP mice were backcrossed 6 generations onto the C3HeB/FeJ background. All mice were bred and maintained in a specific pathogen-free facility at the University of Washington. All procedures were approved by the University of Washington Institutional Animal Care and Use Committee.
MBP79–87 (DENPVVHFF) and SV40 TAg (SEFLLEKRI) were from Genemed Synthesis, Inc.
EAE was induced in C3HeB/Fej mice by rMOG immunization as described25. EAE was induced in 8.8 mice by adoptive transfer of CD4+ T cells from rMOG-immunized C3HeB/Fej mice that were re-stimulated in vitro with MOG97–114 as described25. CNS tissues were harvested from perfused naïve or EAE mice (1–3 days post onset, clinical score >3). DCs, macrophages, microglia and endothelial cells were isolated from tissues digested with 2 mg/ml collagenase D (Roche Applied Science) and 20 ng/ml of DNase in PBS for 30 min at 37 °C. Cells were isolated from mechanically dissociated tissues for CD62L staining. Oligodendrocytes and astrocytes were isolated from tissues digested with 1 mg/ml papain (Worthington Biochemical Corp.) and 20 ng/ml DNase in HBSS. Tissues were gently triturated and PBS containing 5% fetal bovine serum was added to stop digestion. Digested tissue was filtered through a stainless steel mesh and centrifuged. CNS cells were isolated from the interface of a 30/70% percoll gradient centrifuged without brake for 20 min at 250 g.
CNS cells were incubated with Fc block (clone 2.4G2; eBioscience) in 5% normal mouse serum for 15 min at 25°C, washed and stained with antibodies for 30 min at 4 °C. Biotinylated 12H4 or control mouse IgG2a or anti-Kb antibody was detected with PE-conjugated streptavidin (BD). Antibodies from BD were: APC-anti-CD8 (clone 2.43), FITC-anti-CD11c (clone HL3), APC-anti-CD31 (clone MEC 13.3), PE-Cy5-anti-B220 (clone RA3–6B2), PerCP-Cy5.5-anti-CD62L (clone MEL-14), PE-anti-CD80 (clone 16-10A1), PE-anti-CD86 (clone GL1), FITC-anti-H-2Kk (clone 36-7-5), FITC-anti-Thy1.2 (clone 53-2.1); from eBioscience: FITC-anti-CD8 (clone 53.6.7), PE-Cy7-anti-CD11b (clone M1/70), FITC-anti-CD103 (clone 2E7), PerCP-Cy5.5-anti-Ly6C (clone HK1.4), APC-anti-F4/80 (clone BM8), PerCP-eFluor 710-anti-I-Ak (clone 10-3.6), purified mouse IgG2a; from Biolegend: APC-anti-CD11c (clone N418), APC-Cy7-anti-CD45 (clone 37-F11); and from R&D: APC-anti-CCR2 (clone 475301), NL637-anti-O4 (clone O4), CX3CR1 (polyclonal). CX3CR1 staining was carried out prior to incubation with other antibodies and detected with APC-conjugated donkey anti-goat IgG (R&D). Intracellular IFN- γ staining was performed according to manufacturer’s instructions (BD Biosciences) on 8.6 or TAg-specific T cells cultured with CNS cells (T cell:APC ratio 1:1; 1:2 for fixed CNS cells). Cells were analyzed with a FACSCanto flow cytometer (BD Biosciences). Intracellular staining for TNF-α was performed on CNS cells cultured in complete media for 3 h and analyzed using a LSRII flow cytometer (BD Biosciences). CNS cells were sorted using a FACS ARIA (BD Biosciences). PLP-GFP mice and GFAP-GFP mice were used to sort GFP+ oligodendrocytes and astrocytes, respectively. Endothelial cells were sorted based on CD31 expression.
MBP–H2-Kk complexes were generated in house with a construct encoding H-2Kk provided by the National Institutes of Allergy and Infectious Diseases Tetramer Core Facility. C3HeB/Fej mice were subcutaneously immunized with 20 μg MBP–H2-Kk emulsified in complete Freund’s adjuvant (CFA, Sigma-Adrich) and boosted twice at three week intervals with subcutaneous injections of 10 μg MBP–H2-Kk in incomplete Freund’s adjuvant. Two weeks after the last boost, mice were injected intravenously with 10 μg soluble MBP–H2-Kk. Cells were harvested from spleen and draining lymph nodes four days later, fused to X63.Ag8.653 mouse myeloma cells and selected in HAT complete medium. Hybridoma supernatants were screened using a cell-based ELISA assay. RMA-S–H2-Kk cells were incubated with 5 μg/ml recombinant β-2-microglobulin and either 20 μM MBP peptide or no peptide overnight at 25° C. Cells were washed, fixed with 0.5% paraformaldehyde overnight at 4° C and plated (1×105 per well) in 96-well U bottom plates (Becton Dickinson) that had been blocked with complete medium. Hybridoma supernatant was added and the cells were incubated for 90 minutes at 25°C, washed with PBS/Tween 20 and incubated with horseradish peroxidase-conjugated goat anti-mouse IgG antibody (Jackson Immunoresearch) for 90 min at 25°C before development. Hybridomas demonstrating high absorbance specifically with peptide-pulsed RMA-S–H2-Kk cells were characterized by flow cytometry for binding to RMA-S–H2-Kk cells pulsed with MBP or TAg peptide.
Naïve 8.6 splenocytes were cultured with 0.5 μM MBP peptide in RPMI 1640 complete medium, split on day 3 with complete medium containing 20 IU/ml IL-2 and used 7–20 days after stimulation. Effector TAg-specific T cells were generated by immunizing C3HeB/FeJ mice subcutaneously with 200 μg TAg peptide in CFA and culturing cells from draining lymph nodes and spleens with 1 μM TAg peptide and 20 IU/ml IL-2. Cells were restimulated with 0.5 μM peptide on day 14 and used for experiments 7 days later.
ELISPOT for IFN- γ was performed as previously described 25 using sorted CNS cells (1–10×104) and 1×105 effector 8.6 T cells without adding exogenous antigen. T cell proliferation was assessed by incubating sorted CNS cells with naive 8.6 CD8+ T cells (1×104) purified by negative selection using an autoMACS separator (Miltenyi Biotec) in a 96 well U-bottom plate for 72 h. 1 μCi of 3H-thymidine was added for the last 16 h.
CD11c+CD103Int12H4+ and CD11c+CD103−12H4− cells were sorted from EAE mice, RNA extracted using a RNeasymicro kit (Qiagen), and first-strand cDNA synthesized using SuperScript II (Invitrogen). Quantitative PCR was performed (see Supplementary Table 1 for oligonucleotide primers) on an ABI 7300 RealTime PCR System (Applied Biosystems). Gene expression was normalized to values for HPRT.
Unpaired two-tailed Student t test was used for statistical analyses. P < 0.05 was considered significantly difference.
FN2COMPETING FINANCIAL INTERESTS
The authors declare no competing financial interests.
Q.J. conducted most of the experiments and analyzed the data; L.C. assisted with some RT-PCR experiments and performed and analyzed in vivo experiments demonstrating activation of CD8+ T cells within the CNS and critiqued the manuscript; Q.J. and J.M.G. designed the study and wrote the manuscript, J.M.G. secured the funding.
The authors thank N. Mitiku, S. Lee, E. Pierson and S. Swarts for critical reading of the manuscript. This work was supported by grants from the National Institutes of Health (AIO72737 and AI073748) to J.M. Goverman.
|1.||Goverman J. Autoimmune T cell responses in the central nervous systemNat Rev Immunol9393407Year: 200919444307|
|2.||Tompkins SM,et al. De novo central nervous system processing of myelin antigen is required for the initiation of experimental autoimmune encephalomyelitisJ Immunol16841734183Year: 200211937578|
|3.||Kawakami N,et al. The activation status of neuroantigen-specific T cells in the target organ determines the clinical outcome of autoimmune encephalomyelitisJ Exp Med199185197Year: 200414734524|
|4.||Greter M,et al. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosisNat Med11328334Year: 200515735653|
|5.||King IL,Dickendesher TL,Segal BM. Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating diseaseBlood11331903197Year: 200919196868|
|6.||Mildner A,et al. CCR2+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous systemBrain13224872500Year: 200919531531|
|7.||McRae BL,Vanderlugt CL,Dal Canto MC,Miller SD. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitisJ Exp Med1827585Year: 19957540658|
|8.||Tuohy VK,et al. The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosisImmunol Rev16493100Year: 19989795767|
|9.||Mars LT,Saikali P,Liblau RS,Arbour N. Contribution of CD8 T lymphocytes to the immuno-pathogenesis of multiple sclerosis and its animal modelsBiochim Biophys Acta1812151161Year: 201120637863|
|10.||Zozulya AL,Wiendl H. The role of CD8 suppressors versus destructors in autoimmune central nervous system inflammationHum Immunol69797804Year: 200818723060|
|11.||Babbe H,et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reactionJ Exp Med192393404Year: 200010934227|
|12.||Gay FW,Drye TJ,Dick GW,Esiri MM. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesionBrain120 Pt 814611483Year: 19979278635|
|13.||Bitsch A,Schuchardt J,Bunkowski S,Kuhlmann T,Bruck W. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammationBrain123 Pt 611741183Year: 200010825356|
|14.||Neumann H,Medana IM,Bauer J,Lassmann H. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseasesTrends Neurosci25313319Year: 200212086750|
|15.||Jacobsen M,et al. Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patientsBrain125538550Year: 200211872611|
|16.||Junker A,et al. Multiple sclerosis: T-cell receptor expression in distinct brain regionsBrain13027892799Year: 200717890278|
|17.||Skulina C,et al. Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and bloodProc Natl Acad Sci USA10124282433Year: 200414983026|
|18.||Crawford MP,et al. High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assayBlood10342224231Year: 200414976054|
|19.||Zang YC,et al. Increased CD8+ cytotoxic T cell responses to myelin basic protein in multiple sclerosisJ Immunol17251205127Year: 200415067096|
|20.||Mars LT,et al. CD8 T cell responses to myelin oligodendrocyte glycoprotein-derived peptides in humanized HLA-A*0201-transgenic miceJ Immunol17950905098Year: 200717911594|
|21.||Huseby ES,et al. A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosisJ Exp Med194669676Year: 200111535634|
|22.||Sun D,et al. Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 miceJ Immunol16675797587Year: 200111390514|
|23.||Friese MA,et al. Opposing effects of HLA class I molecules in tuning autoreactive CD8+ T cells in multiple sclerosisNat Med1412271235Year: 200818953350|
|24.||Perchellet A,Stromnes I,Pang JM,Goverman J. CD8+ T cells maintain tolerance to myelin basic protein by ‘epitope theft’Nat Immunol5606614Year: 200415146180|
|25.||Stromnes IM,Cerretti LM,Liggitt D,Harris RA,Goverman JM. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cellsNat Med14337342Year: 200818278054|
|26.||Huseby ES,Ohlen C,Goverman J. Cutting edge: myelin basic protein-specific cytotoxic T cell tolerance is maintained in vivo by a single dominant epitope in H-2k miceJ Immunol16311151118Year: 199910415003|
|27.||Fischer HG,Reichmann G. Brain dendritic cells and macrophages/microglia in central nervous system inflammationJ Immunol16627172726Year: 200111160337|
|28.||Bailey SL,Schreiner B,McMahon EJ,Miller SD. CNS myeloid DCs presenting endogenous myelin peptides ‘preferentially’ polarize CD4+ T(H)-17 cells in relapsing EAENat Immunol8172180Year: 200717206145|
|29.||Deshpande P,King IL,Segal BM. Cutting edge: CNS CD11c+ cells from mice with encephalomyelitis polarize Th17 cells and support CD25+CD4+ T cell-mediated immunosuppression, suggesting dual roles in the disease processJ Immunol17866956699Year: 200717513712|
|30.||Saederup N,et al. Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-red fluorescent protein knock-in micePLoS One5e13693Year: 201021060874|
|31.||Sica A,et al. Bacterial lipopolysaccharide rapidly inhibits expression of C-C chemokine receptors in human monocytesJ Exp Med185969974Year: 19979120403|
|32.||Shortman K,Heath WR. The CD8+ dendritic cell subsetImmunol Rev2341831Year: 201020193009|
|33.||Sathe P,et al. The acquisition of antigen cross-presentation function by newly formed dendritic cellsJ Immunol18651845192Year: 201121422244|
|34.||Satpathy AT,Murphy KM,Kc W. Transcription factor networks in dendritic cell developmentSemin Immunol23388397Year: 201121924924|
|35.||Satpathy AT,et al. Zbtb46 expression distinguishes classical dendritic cells and their committed progenitors from other immune lineagesJ Exp Med20911351152Year: 201222615127|
|36.||Meredith MM,et al. Expression of the zinc finger transcription factor zDC (Zbtb46, Btbd4) defines the classical dendritic cell lineageJ Exp Med20911531165Year: 201222615130|
|37.||Serbina NV,Salazar-Mather TP,Biron CA,Kuziel WA,Pamer EG. TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infectionImmunity195970Year: 200312871639|
|38.||Feng JM. Minireview: expression and function of golli protein in immune systemNeurochem Res32273278Year: 200717024569|
|39.||Chastain EM,Duncan DS,Rodgers JM,Miller SD. The role of antigen presenting cells in multiple sclerosisBiochim Biophys Acta1812265274Year: 201120637861|
|40.||Galea I,et al. An antigen-specific pathway for CD8 T cells across the blood-brain barrierJ Exp Med20420232030Year: 200717682068|
|41.||Ji Q,Perchellet A,Goverman JM. Viral infection triggers central nervous system autoimmunity via activation of CD8+ T cells expressing dual TCRsNat Immunol11628634Year: 201020526343|
|42.||Serafini B,et al. Dendritic cells in multiple sclerosis lesions: maturation stage, myelin uptake, and interaction with proliferating T cellsJ Neuropathol Exp Neurol65124141Year: 200616462204|
|43.||Cudrici C,et al. Dendritic cells are abundant in non-lesional gray matter in multiple sclerosisExp Mol Pathol83198206Year: 200717662270|
|44.||Fitzner D,et al. Selective transfer of exosomes from oligodendrocytes to microglia by macropinocytosisJ Cell Sci124447458Year: 201121242314|
|45.||Wakim LM,Bevan MJ. Cross-dressed dendritic cells drive memory CD8+ T-cell activation after viral infectionNature471629632Year: 201121455179|
|46.||Davis DM. Intercellular transfer of cell-surface proteins is common and can affect many stages of an immune responseNat Rev Immunol7238243Year: 200717290299|
|47.||Matheoud D,et al. Cross-presentation by dendritic cells from live cells induces protective immune responses in vivoBlood11544124420Year: 201020308597|
|48.||Calzascia T,et al. Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCsImmunity22175184Year: 200515723806|
|49.||Bartholomaus I,et al. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesionsNature4629498Year: 200919829296|
|50.||Jurewicz A,Biddison WE,Antel JP. MHC class I-restricted lysis of human oligodendrocytes by myelin basic protein peptide-specific CD8 T lymphocytesJ Immunol16030563059Year: 19989510211|
|51.||Kornek B,et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesionsAm J Pathol157267276Year: 200010880396|
Previous Document: A novel label-free electrochemical microRNA biosensor using Pd nanoparticles as enhancer and linker.
Next Document: Elevated expression of C3G protein in the peri-infarct myocardium of rats.